Chemotherapy cures a high proportion of patients with metastatic testicular germ-cell cancer. Standard treatment is based on cisplatin-containing combinations, most commonly BEP (bleomycin, etoposide and cisplatin) or EP in selected situations. The number and type of cycles depend on whether the tumour is seminoma or non-seminoma and on the IGCCCG prognostic group. Because cure rates are high, treatment is planned carefully to avoid under-treatment while also reducing unnecessary long-term toxicity. Fertility preservation should be discussed before chemotherapy whenever possible.

When is chemotherapy used?

• Metastatic seminoma or non-seminoma
• Marker-positive disease after orchidectomy
• Relapse after surveillance or other initial treatment
• Adjuvant treatment in selected stage I patients after risk discussion
• Salvage therapy for disease that relapses after first-line chemotherapy

Common first-line regimens

BEP combines bleomycin, etoposide and cisplatin. EP omits bleomycin and uses additional cycles in certain good-risk situations where bleomycin is unsuitable. More intensive regimens are used for selected intermediate/poor-risk or salvage settings under specialist oncology care.

Short-term side effects

• Nausea, appetite change and fatigue
• Low blood counts and infection risk
• Hair loss
• Kidney and electrolyte effects from cisplatin
• Numbness/tingling and hearing changes
• Bleomycin-related lung toxicity
• Blood-clot risk

Long-term survivorship

Because many patients live for decades after cure, late effects matter: hearing loss, neuropathy, reduced fertility, cardiovascular/metabolic risk, kidney impairment and second malignancy risk are monitored according to exposure and symptoms. Smoking substantially increases pulmonary risk and is particularly important around bleomycin.

How response is assessed

AFP, beta-hCG and LDH are followed during treatment when they were elevated. CT imaging assesses radiological response. Management of residual masses differs between seminoma and non-seminoma; in non-seminoma, post-chemotherapy residual-mass surgery may be important because teratoma is chemotherapy-resistant.

BEP and EP are not interchangeable cycle-for-cycle

For good-risk metastatic disease, standard options commonly include three cycles of BEP or four cycles of EP when bleomycin is contraindicated. Omitting bleomycin usually changes the number of cycles. Regimen selection should therefore follow germ-cell tumour protocols rather than ad-hoc drug substitution.

Marker decline is part of response assessment

AFP and beta-hCG are followed through chemotherapy when elevated. Persistently abnormal kinetics can signal higher-risk disease, but one unexpected value should be confirmed and interpreted with the whole treatment course. CT is performed at protocol-defined times rather than after every minor marker fluctuation.

Residual masses after chemotherapy are managed differently by histology

In non-seminoma, residual retroperitoneal masses may contain viable cancer, teratoma or fibrosis; teratoma is resistant to chemotherapy and can require post-chemotherapy RPLND. In seminoma, residual masses are handled differently and routine surgery is far less common.

Why germ-cell chemotherapy is protocol driven

Testicular cancer is unusually curable even when it has spread, which makes correct first-line treatment especially important. Cisplatin dose intensity, the planned number of cycles and the role of bleomycin are not casually interchangeable. Treatment is therefore best delivered according to established germ-cell tumour protocols, with toxicity managed aggressively without unintentionally reducing curative treatment intensity.

When to seek earlier medical review

During chemotherapy, fever, rigors, severe breathlessness, chest pain, persistent vomiting, confusion or rapidly worsening weakness requires urgent oncology assessment. New cough/breathlessness with bleomycin, hearing change or significant neuropathy should be reported early.

What to bring to your consultation

• Orchidectomy HPE and stage/risk group
• Marker trend
• Current chemotherapy regimen/cycle records
• Renal function, blood counts and any hearing/lung baseline tests

Questions to ask your doctor

• Why is BEP or EP preferred in my prognostic group?
• How will marker decline be monitored during treatment?
• If a residual mass remains after chemotherapy, does my histology make surgery likely?

FAQs

Related reading

• Testicular Cancer: Symptoms and Treatment
• Painless Testicular Lump: When to Worry
• Tumor Markers AFP, Beta-hCG and LDH Explained
• Radical Orchidectomy Explained
• Testicular Cancer and Fertility
• Chemotherapy for Advanced Prostate Cancer
• Testicular Cancer Stages Explained
• Surveillance After Testicular Cancer Treatment
• Urologist in Latur

References

• European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/testicular-cancer/chapter/diagnostic-evaluation
• European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Disease Management https://uroweb.org/guidelines/testicular-cancer/chapter/disease-management
• European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Follow-up After Curative Therapy https://uroweb.org/guidelines/testicular-cancer/chapter/followup-after-curative-therapy
• National Cancer Institute. Testicular Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq